Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 -0.47%76 Return-on-Tangible-Equity is 11.75% as of Mar. 2026, which is 1% above its 10-year median of 11.60. GuruFocus rates ROCO:3118 with a GF Score™ of 76/100 and a GF Value™ of NT$33.78 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,198 Biotechnology companies, Level Biotechnology ranks better than 89.07% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Level Biotechnology's annualized net income for the quarter that ended in Mar. 2026 was NT$69.2 Mil. Level Biotechnology's average shareholder tangible equity for the quarter that ended in Mar. 2026 was NT$588.8 Mil. Therefore, Level Biotechnology's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 11.75%.
The historical rank and industry rank for Level Biotechnology's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:3118'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.62 Med: 11.6 Max: 13.98
Current: 13.51
During the past 13 years, Level Biotechnology's highest Return-on-Tangible-Equity was 13.98%. The lowest was 7.62%. And the median was 11.60%.
ROCO:3118's Return-on-Tangible-Equity is ranked better than 89.07% of 1198
companies
in the Biotechnology industry
Industry Median: -42.305
vs ROCO:3118: 13.51
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Level Biotechnology Return-on-Tangible-Equity Related Terms
Level Biotechnology Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Level Biotechnology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.75% mean?
Level Biotechnology (ROCO:3118) has a Return-on-Tangible-Equity of 11.75% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Level Biotechnology and its competitors. This is near median its historical median of 11.60. Over the past decade, Level Biotechnology's Return-on-Tangible-Equity has ranged from 7.62 to 13.98. According to the industry distribution chart, Level Biotechnology ranks #131 out of 1198 companies in the Biotechnology industry, placing it in the top 10.9%.
Is Level Biotechnology's Return-on-Tangible-Equity too high?
Level Biotechnology's current Return-on-Tangible-Equity of 11.75% is near median its 10-year median of 11.60. Over the past 10 years, this metric has ranged from a low of 7.62 to a high of 13.98. Based on the distribution chart, Level Biotechnology ranks #131 out of 1198 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Level Biotechnology has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #131 out of 1198 companies for Return-on-Tangible-Equity. This places Level Biotechnology in the top 11% of its industry — outperforming the majority of peers. Historically, Level Biotechnology's own Return-on-Tangible-Equity has ranged from 7.62 to 13.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Level Biotechnology and its competitors. Level Biotechnology's current Return-on-Tangible-Equity is 11.75%, which is near median its own 10-year median of 11.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.78, compared to a current price of NT$31.80 — trading 5.9% below its estimated fair value. The current Return-on-Tangible-Equity is 11.75%, which is near median its 10-year median of 11.60. Level Biotechnology's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current Return-on-Tangible-Equity is 11.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.80 is trading 5.9% below its estimated GF Value™ of NT$33.78.
GuruFocus considers Level Biotechnology to be Fairly Valued.
Key valuation signals for ROCO:3118:
Return-on-Tangible-Equity: 11.75% (near median its 10-year median of 11.60)
GF Value™: NT$33.78 vs. price of NT$31.80 (5.9% below fair value)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
76GF Score
Get the complete analysis for ROCO:3118
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
